Anebulo Pharmaceuticals Inc
(ANEB)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
(Values in U.S. thousands)
| 06-2025 | 06-2024 | 06-2023 | 06-2022 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,485 | -8,202 | -11,732 | -6,826 | -30,253 |
| Depreciation Amortization | 382 | 151 | N/A | N/A | N/A |
| Accounts receivable | -73 | N/A | N/A | N/A | 4 |
| Accounts payable and accrued liabilities | 68 | -378 | 154 | 271 | 110 |
| Other Working Capital | 306 | -799 | 1,165 | 908 | -1,445 |
| Other Operating Activity | 1,452 | 1,137 | 731 | 210 | 26,713 |
| Operating Cash Flow | $-6,350 | $-8,091 | $-9,683 | $-5,437 | $-4,871 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | N/A | -201 |
| Common Stock Issued | 15,000 | N/A | 6,699 | N/A | 20,605 |
| Other Financing Activity | -117 | -62 | -317 | 0 | 1,428 |
| Financing Cash Flow | $14,883 | $-62 | $6,382 | $N/A | $21,832 |
| Beginning Cash Position | 3,094 | 11,247 | 14,549 | 19,986 | 3,025 |
| End Cash Position | 11,628 | 3,094 | 11,247 | 14,549 | 19,986 |
| Net Cash Flow | $8,534 | $-8,153 | $-3,301 | $-5,437 | $16,961 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,350 | -8,091 | -9,683 | -5,437 | -4,871 |
| Free Cash Flow | -6,350 | -8,091 | -9,683 | -5,437 | -4,871 |